Cytomegalovirus (CMV) is a type of herpes virus. Primary infection is usually asymptomatic but may cause a flu or glandular fever like illness, leading to a lifelong infection in all age groups. The virus can reactivate from its latent state and it is commonly shed asymptomatically in various bodily secretions, such as nasopharyngeal secretions and urine. More severe disease may occur in individuals with impaired immunity such as foetuses, neonates and patients of any age who have been immuno-suppressed by disease or treatment.

Infection frequently occurs in childhood and in the UK it is estimated that 50-60% of adults are CMV positive. As CMV is very common, most adults will have been infected earlier in life and will have developed an immune response to the virus in the form of immunoglobulin (Ig) G, i.e. they will be CMV IgG positive.

A person can become infected with CMV in several ways; most commonly via person to person contact, through exposure to body fluids. A mother can infect her unborn baby in utero or her newborn baby via breast feeding. Most disease in immuno-compromised patients occurs through these routes or from reactivation of a previous CMV infection.
CMV is less commonly transmitted by receiving donated blood or organs from a person who is carrying CMV, or from donors who have acute CMV infection but are CMV IgG negative as they have not yet formed an immune response but have the circulating virus in their blood. There is a 6-8 week window period before seroconversion. Transmission of CMV present in blood components can give rise to primary infection in CMV negative patients or to reinfection in previously infected patients.

**Why is CMV important?**
CMV can cause a potentially life threatening infection in patients who cannot form an effective immune response. CMV disease is the commonest infection problem in the post-transplant period and the commonest cause of congenital infection, leading to neuro development abnormalities in approximately 1 in 1000 babies born in the UK.

**There are certain groups at particular risk of severe disease:**

- **Foetuses and neonates:**
  CMV is the most common cause of congenital infection in the developed world, affecting 1-2% of infants worldwide (Luck and Sharland, 2009b), and 0.3-0.4% in the UK (Griffiths et al, 1991). CMV is estimated to cause up to 12% of all sensorineural hearing loss (Peckham et al, 1987) and 10% of cerebral palsy. Primary infection may increase the risk of spontaneous abortion, stillbirth and foetal hydrops. Ophthalmic complications, including chorioretinitis, cataract and blindness, occur in 10-20% of congenital cases following primary maternal infection.

- **Immuno-compromised patients:**
  Immuno-compromised patients who have not been infected with CMV (CMV negative) are also at risk from transfusion transmitted CMV, infection through person to person contact, stem cells or solid organ transplants. The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) undertook a literature review and risk assessment and identified that randomised studies and systematic reviews demonstrated that leucodepletion (i.e. the blood component is filtered to reduce white cells) is as effective as CMV IgG negative blood components. These patients should receive leucodepleted blood; CMV IgG negative donations are not required. This approach has also been adopted in other developed countries.
What do CMV test results mean?
Please refer to the full version of this leaflet on the Hospitals and Science website: http://hospital.blood.co.uk/safe_use/general_educational_resources/index.asp

Who needs to receive CMV IgG negative blood components?
In March 2012, SaBTO released a position statement containing the following indications for the provision of CMV IgG negative blood components:

- Intra-uterine transfusions
- Neonates up to 28 days post expected date of delivery
- Pregnancy:
  - Elective transfusions during pregnancy (not during labour or delivery)
  - If in an emergency situation, it is not possible to provide CMV negative blood components, leucocyte depleted components may be used.

Organ transplant patients do not require CMV IgG negative blood components. CMV IgG negative red cells and platelets may be replaced with leucodepleted blood components for adults and children post haemopoietic stem cell transplantation for all patient groups, including negative donors and recipients.

Individual transplant centres, however, should have a policy of CMV monitoring by PCR for haemopoietic stem cell transplants and some groups of transplant patients. This practice allows early detection of any possible CMV infection (whether transfusion-transmitted, acquired or reactivated). There has been variability of practice with many centres repeatedly monitoring CMV IgG positive recipients for reactivation by PCR, SaBTO suggested that this practice should be extended to CMV IgG negative individuals.

What is a CMV negative blood component?
CMV negative blood components are those that are collected from donors who have been tested and found negative for CMV IgG antibodies. A proportion of donations are screened by the Blood Services for CMV IgG antibodies to provide a ‘CMV negative’ inventory for red cells and platelets, which are provided to hospitals on request.
Depending on age group, 25-40% of UK blood donors are CMV IgG antibody positive (this is a smaller number than that stated above for ‘adults’, as the prevalence of CMV IgG positivity increases with age and donor populations are younger than screened adult populations).

**How is the risk of CMV transmission through blood components reduced?**

The virus can be transmitted through white cells contained in blood components e.g. units of red cells and platelets. In the UK, blood components (except white cell components) are leucocyte-depleted to reduce the transmission risk of variant Creutzfeldt Jakob Disease (vCJD). However, it can not be guaranteed that the risk of transmitting CMV is completely eliminated (Vamvakas, 2005); in the same way that CMV IgG testing is not a guarantee.

Despite the theoretical risk of CMV transmission, fresh frozen plasma (FFP) and other plasma components have not been shown to transmit CMV so the CMV status is not shown on the label for these components.

Granulocyte components should be provided as CMV negative for all CMV negative patients as these components can not be leucocyte depleted. A medical decision may be made to transfuse units which are not CMV tested or which are known to be CMV IgG positive into a CMV negative patient if the urgency to treat a non responsive bacterial or fungal infection outweighs the risks of potentially developing CMV infection at a later stage.

**For further information contact your Transfusion Practitioner, Consultant Haematologist or Hospital Transfusion Laboratory**

References:


